Novo Nordisk has initiated legal proceedings against Hims & Hers to protect its patent rights related to the weight-loss medications Wegovy and Ozempic, seeking to prevent the sale of unsafe knockoff products. This comes as the company celebrates FDA approval for a higher dose of Wegovy, which elevates Novo Nordisk's profile in the obesity drug market but also raises concerns over potential U.S. drug pricing negotiations that could compress earnings. As the competitive landscape intensifies, particularly from Eli Lilly, Novo Nordisk aims to stabilize its market position while navigating these challenges.
“On February 9, 2026, Novo Nordisk also escalated its enforcement actions by suing Hims & Hers for infringing US Patent No. 8,129,343.”
“Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knockoff Wegovy and Ozempic.”
“Novo Nordisk (NYSE:NVO) received FDA approval for a higher dose of its obesity drug Wegovy under the National Priority Voucher program. The approval came through a fast track process that is currently drawing attention from regulators and lawmakers.”
“For investors looking at NYSE:NVO, this development links product expansion directly to regulatory scrutiny. The way the June meeting shapes future use of the voucher program could influence timing and pathways for any additional obesity-related approvals across the sector.”
“Key Considerations: The higher dose Wegovy approval under a priority voucher ties the product story more tightly to U.S. regulatory debate, which may shape perception of Novo Nordisk's obesity franchise.”
“Pfizer (PFE), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), and Novo Nordisk (NVO) also face exposure to potential U.S. drug pricing negotiations that could compress sector earnings. Trump’s direct drug price negotiations with manufacturers—already forcing discounts on weight loss drugs—could expand across more drug classes and repriced the entire pharma sector downward if the framework becomes broader policy.”
“Under deals already struck, Eli Lilly and Novo Nordisk agreed to significant price discounts on weight loss drugs in exchange for three-year tariff relief and FDA priority review vouchers.”
“If that framework expands to cover more drug classes or more companies in this portfolio, revenue forecasts across the sector would need to be revised downward.”
“Novo Nordisk anticipates introducing Awiqli in the FlexTouch device in the United States in the second half of 2026.”
“Beyond weight loss, Novo Nordisk has earned some important label expansions for Wegovy, including in treating metabolic dysfunction-associated steatohepatitis (MASH), a disease linked to obesity where there is a high unmet need. It is also indicated to reduce the risk of major cardiovascular events in patients with cardiovascular disease who are either overweight or obese.”
“Novo Nordisk might indeed be a bargain, as the stock could bounce back as it makes solid clinical and regulatory progress over the next few years. But it is still not a better buy than Eli Lilly.”
“Novo Nordisk might indeed be a bargain, as the stock could bounce back as it makes solid clinical and regulatory progress over the next few years.”
